stockrowGilead Sciences, Inc. (GILD) vs Novartis AG (NVS)
- Gilead Sciences, Inc. GILD 167.89 +0.19%
- Novartis AG NVS 162.16 +0.14%
Gilead Sciences, Inc. and Novartis AG are both Drug Manufacturers General companies. Novartis AG is the larger, with a market value of $296.4B against $207.8B — 1.4× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Novartis AG trades at 30.9×. Gilead Sciences, Inc. grew revenue faster over the last twelve months: 6.54% against 1.76%. Novartis AG has the higher net margin (17.5% vs −12.5%) and the higher return on invested capital (12.1% vs −4.51%). Both pay a dividend; Novartis AG yields more (2.93% vs 1.94%). Across the 22 metrics below, Novartis AG leads on 13 and Gilead Sciences, Inc. on 9.
Valuation
Profitability
| Metric | GILD | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.93% | 74.92% | 73.01% |
| Operating margin | (7.63%) | 25.18% | 18.34% |
| Net margin | (12.47%) | 17.49% | 7.31% |
| Free cash flow margin | 44.47% | 24.66% | 18.52% |
| Return on equity | (22.45%) | 24.37% | 5.80% |
| Return on assets | (7.03%) | 8.94% | 2.28% |
| Return on invested capital | (4.51%) | 12.05% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack